Novimmune SA has brought 7 monoclonal antibodies to clinical development stage, one of which, Emapalumab, has been approved by the FDA in 2018.

After the successful divestment of Emapalumab related activities, we now focus on our bispecific technology to build a pipeline of multispecific antibodies under the brand Light Chain Bioscience.

Location

14, Chemin des Aulx, 1228 Plan-les-Ouates, Switzerland

Facts & figures
  • Type of organization

    Private company

  • Year of foundation

    1999

  • Number of employees in Switzerland

    50-149

Key business